Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study
The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is:
- To investigate the predictive efficacy of the genetic risk score for T1DM in determining whether diabetic patients will progress to insulin deficiency;
- To compare the differences in genetic characteristics between the insulin-deficient cohort and the non-insulin-deficient cohort.
This study is a nested case-control study, in which a case group and a control group are set up for the collection of observational indicators. Case group: Diabetic patients who "progressed to insulin deficiency" and those who "progressed to severe insulin deficiency". Control group: Patients who did not progress to insulin deficiency. The study period is 3 years.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Hunan
-
Changsha、Hunan、中国、410011
- 募集
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
-
コンタクト:
- Yang Xiao, MD/PhD
- 電話番号:86-0731-85292154
- メール:xiaoyang29@csu.edu.cn
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
This study will enroll newly-diagnosed diabetic patients whose clinical subtype is unclear. Participants must be aged between 14 and 50 years, with a diabetes diagnosis within the past year, confirmed by standard American Diabetes Association (ADA) criteria. A key pathophysiological criterion is a peak C-peptide level < 200 pmol/L, suggesting impaired insulin secretion.
Key Exclusion Criteria: Patients will be excluded for conditions that could confound the etiology of diabetes or pose additional risks, including:
Specific diabetes subtypes (e.g., gestational diabetes, monogenic diabetes, pancreatic diseases).
Comorbidities such as malignant tumors or severe organ dysfunction. Acute metabolic derangements (e.g., ketoacidosis). Conditions limiting life expectancy or ability to participate (e.g., expected survival < 3 years, psychiatric disorders).
Current pregnancy or lactation.
説明
Inclusion Criteria:
- Gender is not restricted.
- Age ranges from 14 to 50 years old.
Diagnosis of diabetes within < 1 year:
- If there are diabetes symptoms and meet any of the following criteria:① Plasma glucose at any time ≥ 11.1 mmol/L (200 mg/dL), or② Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL), or③ Plasma glucose 2 hours after OGTT/post - meal ≥ 11.1 mmol/L (200 mg/dL), or④ HbA1c ≥ 6.5%.
- If there are no diabetes symptoms, another test on a different day is required for diagnosis.
- Newly - diagnosed diabetes patients whose type diagnosis is considered unclear clinically.
Exclusion Criteria:
- Peak C-peptide < 200 pmol/L;
- Gestational diabetes, monogenic diabetes (neonatal diabetes, MODY), exocrine pancreatic diseases (cystic fibrosis), diabetes caused by drugs or chemicals;
- Those who have been under long-term treatment with hormones or immunosuppressants;
- Pregnant or lactating women;
- Those with concurrent malignant tumors or severe heart, liver, and kidney diseases;
- Those with an expected survival time of less than 3 years;
- Those with mental disorders or unable to cooperate with the investigation for other reasons;
- Acute phase of diabetic ketoacidosis;
- Stress conditions such as severe infection, fever, trauma, and major surgery;
- Patients lacking major clinical information;
- Those considered by the researcher as unfit to participate in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Patients with diabetes who 'progress to insulin deficiency and severe insulin deficiency'
Patients with diabetes who 'progress to insulin deficiency' and 'progress to severe insulin deficiency'
|
|
Patients who have not progressed to insulin deficiency
For each case, several controls (1:2) were randomly selected from patients in this cohort who had not progressed to insulin deficiency at the same follow - up time point.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
C-peptide
時間枠:"baseline"、"third year"
|
The primary endpoint is the occurrence of progression to insulin deficiency.
Subjects who "progress to insulin deficiency" are defined as those whose C-peptide level drops to C-peptide < 250 pmol/L during the follow - up period;
|
"baseline"、"third year"
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting and 2 - hour blood glucose
時間枠:"baseline"、"third year"
|
"baseline"、"third year"
|
|
|
Glycosylated hemoglobin
時間枠:"baseline"、"third year"
|
"baseline"、"third year"
|
|
|
Whether insulin treatment is needed
時間枠:"baseline"、"third year"
|
Collect the medical history and current medication information of the subjects.
|
"baseline"、"third year"
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。